Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ulipristal Acetate Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA

NCT02859337
View directory record Official record
Conditions
Obesity, Contraception
Interventions
UPA-ECx1, UPA-ECx2
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Intervention to End Recurrent Unscheduled Bleeding Trial

NCT03118297
View directory record Official record
Conditions
Contraception, Bleeding
Interventions
Ulipristal Acetate, Placebo oral capsule
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives

NCT00089414
View directory record Official record
Conditions
Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
Interventions
Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

NCT01107106
View directory record Official record
Conditions
Contraception
Interventions
ellaOne® (ulipristal acetate)
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
Female only
Enrollment
579 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Lakewood, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 μg of CDB-2914

NCT00791297
View directory record Official record
Conditions
Contraception
Interventions
CDB-2914
Drug
Lead sponsor
Population Council
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

NCT00041899
View directory record Official record
Conditions
Healthy
Interventions
CDB-2914, COB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Mammogram Pretreatment With Ulipristal Acetate

NCT07434128
View directory record Official record
Conditions
Mammography Screening, Breast Density
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Mammogram, Survey Administration, Ulipristal Acetate
Procedure · Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG

NCT02863445
View directory record Official record
Conditions
Obesity
Interventions
Levonorgestrel-based emergency contraception 1.5 mg, Levonorgestrel-based emergency contraception 3.0mg
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Video Messaging About Emergency Contraception

NCT03774368
View directory record Official record
Conditions
Contraception
Interventions
Emergency contraception website, Emergency contraception video
Other
Lead sponsor
Planned Parenthood League of Massachusetts
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

NCT00551616
View directory record Official record
Conditions
Contraception
Interventions
CDB-2914, Levonorgestrel
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
16 Years and older · Female only
Enrollment
2,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Los Angeles, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional

Ulipristal Acetate for Cervical Preparation

NCT03802149
View directory record Official record
Conditions
Termination of Pregnancy
Interventions
Ulipristal Acetate
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Ulipristal Acetate Intermittent Treatment for Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147158
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
61
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EC PK in Women With Normal and Obese BMI

NCT02689804
View directory record Official record
Conditions
Contraception
Interventions
LNG-EC, UPA-EC
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
View directory record Official record
Conditions
Endometriosis
Interventions
Ulipristal
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

NCT03537768
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Levonorgestrel
Drug
Lead sponsor
Kimberly Myer
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
532 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional Results available

Ovarian Function With ENG Implant and UPA Use

NCT04291001
View directory record Official record
Conditions
Contraception
Interventions
ENG implant, oral ulipristal acetate
Device · Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Ulipristal Acetate for Use in Early Pregnancy Loss

NCT05216952
View directory record Official record
Conditions
Missed Abortion, Anembryonic Pregnancy, Non-Viable Pregnancy
Interventions
Ulipristal Acetate Tablets, Misoprostol Pill
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Hillsborough, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

NCT02147197
View directory record Official record
Conditions
Leiomyoma, Uterine Hemorrhage
Interventions
Ulipristal acetate (UPA), Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Efficacy Trial of CDB 2914 for Emergency Contraception

NCT00271583
View directory record Official record
Conditions
Emergency Contraception
Interventions
CDB-2914, levonorgestrel
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
1,672 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2001
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility

NCT03354117
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate 30 MG Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 38 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

NCT01569737
View directory record Official record
Conditions
Emergency Contraception
Interventions
ella
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876
View directory record Official record
Conditions
Leiomyoma
Interventions
CDB-2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
33 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause

NCT00009659
View directory record Official record
Conditions
Postmenopause
Interventions
CDB 2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 25, 2026, 10:15 AM EDT